Criteria for the glucagon provocative test in the diagnosis of gastrinoma

Division of Biological Regulation and Oncology, Department of Surgery, Tohoku University School of Medicine, 1-1 Seriyo-machi, Aoba-ku, Sendai, 980-8574, Japan, .
Surgery Today (Impact Factor: 1.53). 09/2012; 43(11). DOI: 10.1007/s00595-012-0334-2
Source: PubMed


The glucagon provocative test is useful for the diagnosis of gastrinoma. The aim of this study was to determine the criteria for the glucagon provocative test.

This study reviewed 8 patients that underwent the glucagon provocative test preoperatively and in whom the diagnosis was confirmed as gastrinoma histologically. The glucagon provocative test was performed by administering glucagon (20 μg/kg) intravenously, followed by 20 μg/kg h for the next 30 min, and plasma gastrin levels were measured 3 and 1 min before and 3, 5, 7, 10, 15, 20, and 30 min after the administration of glucagon. This study evaluated the peak value of plasma gastrin and the time required to reach the peak.

Two of the 8 patients had multiple endocrine neoplasm type 1. The basal plasma gastrin levels ranged from 524 to 10,300 pg/ml. The time required to reach the peak was 3-10 min for all patients. The increase in the peak from the basal value was 235-8,920 pg/ml, and the percentage of increase was 38-337 %.

These results suggest that a diagnosis of gastrinoma should thus be made when plasma gastrin levels peak within 10 min after glucagon administration, with an increase of greater than 200 pg/ml and greater than 35 % of the basal value.

18 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms, with a prevalence of 1–2 per 100,000 people. Based on the presence or absence of a specific hormone-related clinical syndrome, they are divided into functioning and nonfunctioning. Among the former tumors, insulinomas are the most common. pNETs may be sporadic or associated with hereditary syndromes. The histopathology evaluation should include immunostaining with general (chromogranin A and synaptophysin) and specific neuroendocrine markers, as well as with the proliferation index Ki67. Chromogranin A is currently the most useful neuroendocrine biomarker for diagnosis and follow-up of pNETs. Other specific hormones released by the neoplastic cells can also be included in the biochemical evaluation. For tumor localization both noninvasive and invasive techniques may be used. Debulking procedures and medical therapy are the possible treatment options for pNETs, but surgery is the only modality that offers the possibility of cure.
    Islets of Langerhans, 01/2015: pages 1375-1406; , ISBN: 978-94-007-6685-3
  • [Show abstract] [Hide abstract]
    ABSTRACT: An inhibitory mechanism toward gastrin hypersecretion is significantly different between G-cell hyperplasia and gastrinoma despite the common clinical manifestations; hypergastrinemia and its related persistent gastric ulcers. We recenlty studied the G-cell, d-cell and ECL-cell density in a case of G-cell hyperplasia. The 70-year-old patient has been treated for persistent gastric ulcers with a markedly increased plasma gastrin (5600 pg/mL). The stomach was surgically resected because of the obstruction associated with ulcer scars. The number of G-cells in the pyloric glands was quantified on the surgical specimens and G-cell hyperplasia was histolopathologically identified. Immunostainig of histidine decarboxylate revealed the presence of ECL-cell hyperplasia in the pyloric glands and its density was significantly and positively correlated with G-cell density. Somatostatin immunoreactive cells (d-cells) increased in their number in the oxyntic glands. These results all indicated that hypersecretion of gastrin in G-cell hyperplasia could induce ECL-cell proliferation in a paracrinal manner. In addition, relatively non-prominent endocrinological features in the G-cell hyperplasia compared to gastrinoma could be also related to the paracrinal somatostatin inhibitory effects upon ECL-cells in the pyloric glands. © 2015 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.
    Pathology International 03/2015; 65(5). DOI:10.1111/pin.12276 · 1.69 Impact Factor